Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Fineline Cube Jul 3, 2026
Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Fineline Cube Jul 3, 2026
Policy / Regulatory

Shanghai Outlines Plans to Boost Healthcare and Pharma Industry

Fineline Cube Dec 22, 2022

Liu Wei, director of the market orders and trade division of the Shanghai Commerce Commission,...

Company Drug

Yantai Dongcheng Receives NMPA Approval for F18 PET Imaging Study

Fineline Cube Dec 22, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

Biomica Raises Funds for Tumor Immunity and IBD Drug Development

Fineline Cube Dec 22, 2022

Israel-based start-up Biomica has reportedly raised an undisclosed amount of money via another financing round,...

Company Deals

Redpine Medical Raises ‘Hundreds of Millions’ in Series C Financing Round

Fineline Cube Dec 22, 2022

Redpine Medical, a single-use endoscope maker based in Guangzhou, has reportedly raised “hundreds of millions”...

Company Drug

Yipinhong’s AR882 Receives NMPA Approval for Gout Clinical Trial

Fineline Cube Dec 22, 2022

China-based Yipinhong Pharmacy Co., Ltd (SHA: 300723) has announced that its pipeline candidate AR882, under...

Company Drug

Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor

Fineline Cube Dec 22, 2022

China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) has announced receiving two patents (US11518759B1,...

Company Deals

Sibionics Raises RMB 500 Million in Series D Financing Round

Fineline Cube Dec 21, 2022

Shenzhen-based chronic disease device maker Sibionics has reportedly raised close to RMB 500 million (USD...

Company Deals

Waker Bioscience Raises Angel Funding for ISA Technology Upgrades

Fineline Cube Dec 21, 2022

Waker Bioscience, an integration site analysis (ISA) specialist based in Shanghai, has reportedly raised “tens...

Drug

InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination

Fineline Cube Dec 21, 2022

China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China’s Center...

Company Deals

Ronovo Surgical Raises Pre-Series B Funding for Surgical Robot Development

Fineline Cube Dec 21, 2022

Ronovo Surgical, a minimally invasive surgery device maker based in Shanghai, has reportedly raised “tens...

Company Deals Digital

PingAn Good Doctor Partners to Establish Lifestyle Medicine

Fineline Cube Dec 21, 2022

China-based PingAn Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor,...

Company Deals

JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development

Fineline Cube Dec 21, 2022

China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a...

Company Deals

Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm

Fineline Cube Dec 21, 2022

China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the...

Company Drug

Sirnaomics’ Lead Candidate STP707 Shows Promising Phase I Data

Fineline Cube Dec 21, 2022

Sino-US small interfering RNA (siRNA) specialist Sirnaomics (HKG: 2257) has revealed that its lead pipeline...

Company Drug

Kira Pharmaceuticals Gains NMPA and TGA Approvals for KP104 Phase II Study

Fineline Cube Dec 21, 2022

Sino-US biotech Kira Pharmaceuticals has announced receiving approvals from China’s National Medical Products Administration (NMPA)...

Company Deals

TowardPi Raises RMB 300 Million in Series C Financing Round

Fineline Cube Dec 20, 2022

China-based ophthalmology device maker TowardPi (Beijing) Medical Technology Ltd has reportedly raised close to RMB...

Company Drug

Aosaikang Receives FDA Approval for ASKG915 Clinical Trial

Fineline Cube Dec 20, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...

Company Deals

Pfizer Exercises Option for Sisunatovir Rights with LianBio

Fineline Cube Dec 20, 2022

US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise...

Company Deals

Fosun Pharma Registers Comirnaty Vaccines in Hong Kong

Fineline Cube Dec 20, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced that Comirnaty (BNT162b2) and Comirnaty bivalent...

Company Deals

XtalPi Partners with Singapore’s EDDC to Develop Lung Cancer Treatments

Fineline Cube Dec 20, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with the Experimental Drug...

Posts pagination

1 … 608 609 610 … 690

Recent updates

  • Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors
  • Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older
  • Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
  • Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery
  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Company Drug

Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation

Company

Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.